1. Medtech Insight
  2. >>Geography
  3. >>Europe

MHRA Issues Guidance On Recognizing And Reporting Medtech Software Adverse Events

 
• By Eliza Slawther

When it comes to medtech adverse events incidents may not always be obvious. This is especially the case with medical device software where indirect harm is the most likely outcome of an incident, the UK’s MHRA explains in new guidance.

Medtech App
• Source: Shutterstock

While manufacturers of medical devices will likely be familiar with the reporting of adverse events to regulators that occur after a product is placed on the market, new technologies such as software as a medical device (SaMD) and artificial intelligence as a medical device (AIaMD) may pose new and unexpected risks to patients.

Recent guidance from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) sets out examples of adverse events that manufacturers...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Case Study: Pushing The EU’s IVD Regulation To Its Limits With Next Generation Sequencing

 
• By Amanda Maxwell

Partnership, positive communication and passion were all key in establishing a regulatory route for groundbreaking genetic testing technology for hereditary diseases. So said Fulgent Genetics’ executives interviewed by MTI about their technology’s development pathway.

EU Begins To Define Secondary Uses Of Health Data Under EHDS

 
• By Amanda Maxwell

The medtech industry, eagerly awaiting clear guidance on how healthcare data can be shared and help drive innovation, can have its say.

Should the EU Allow eIFU For Some Lay Devices?

 
• By Amanda Maxwell

Electronic instructions for use are becoming increasingly prevalent in the medtech world, but so far in the EU do not extend to non-professional users.

Rapid Flurry Of Late September EU Regulatory Developments

 
• By Amanda Maxwell

Recent key updates include new guidance on trend reporting, classification decisions, and opportunities for industry.

More from Geography

Blood Volume, Reimagined: Daxor’s BVA Could Slash Testing Time and Save Lives

 
• By Elizabeth Orr

The Daxor Blood Volume Analysis (BVA) is aimed at improving care for heart failure patients. It will allow blood volume to be measured from the patient’s bedside for the first time and is also significantly faster than earlier testing methods.

After Success Of Early Alert Pilot, FDA Builds Out Program To Include All Devices

 
• By Brian Bossetta

The US FDA’s device center says the pilot program launched last year to streamline its recall process has been a success. It’s now starting to build off the program’s achievements, which means patients could be aware of potential safety issues from more types of devices.

EU Begins To Define Secondary Uses Of Health Data Under EHDS

 
• By Amanda Maxwell

The medtech industry, eagerly awaiting clear guidance on how healthcare data can be shared and help drive innovation, can have its say.